- Smith & Nephew has reported underlying revenue growth of 4% for the third quarter of 2019.

The global medical technology business announced today that reported growth was 6.5%, as 390bps benefit of acquisitions outweighed a 140bps currency headwind.

The company's orthopaedics business delivered 3.4% revenue growth, while its sports medicine arm accelerated from strong first half, delivering 6.9% revenue growth.

Smith & Nephew also reported continued mid-teens growth from emerging markets operations, led by another quarter of strong growth in China.

For the full financial year, underlying revenue growth is expected to be in the range 3.5% to 4.5%, while trading profit margin is expected to be around 22.8%.

Graham Baker, CFO, said: 'We're pleased to have delivered organic revenue growth of 4% in the third quarter, a further step towards growing at or above our markets.

'We've built momentum across the first nine months of the year and, at the same time, continued to invest behind our commercial teams and acquisitions to support sustained success over the medium-term.

'As a result, we're confident to increase 2019 revenue guidance again.'

At 8:27am: [LON:SN.] Smith Nephew PLC share price was +19.75p at 1734.75p

Story provided by